Takeda's Actos Could Face Pending Fate Of Rival's Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical could lose U.S. sales of its blockbuster Actos (pioglitazone) if a U.S. FDA review of the drug links it with an increased risk of bladder cancer